Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000127

Drug Information
NameHIF-1alpha
CompanyEnzon
IndicationSolid Tumors, Lymphoma
[ICD9: 140-199, 202.8, 210-229   ICD10: C00-C75, C7A, C7B, C81-C96, D10-D36, D3A]
Phase I    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C20H24N6O3/c1-20(2,3)26-19(27)25-17-15(8-12-10-22-18(21)24-16(
12)23-17)11-6-13(28-4)9-14(7-11)29-5/h6-10H,1-5H3,(H4,21,22,23,24
,25,26,27)
InChIKeyNHJSWORVNIOXIT-UHFFFAOYSA-N
Canonical SMILESCC(C)(C)NC(=O)NC1=C(C=C2C=NC(=NC2=N1)N)C3=CC(=CC(=C3)OC)OC    
Therapeutic ClassAntineoplastic Agents
PubChem Compound IDCID 5328127.
ClinicalTrials.govNCT00522652;
TargetHypoxia-inducible factor 1 alphaInhibitor[1]
Ref 1A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608. Epub 2008 Oct 30. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543